Serological and molecular survey of toxoplasmosis in renal transplant recipients and hemodialysis patients in Kashan and Qom regions, central Iran

Figures & data

Table 1. Serological findings among RTR, HD and control groups.

IgG concentration	RTR (n = 50) No (%)	HD (n = 135) No (%)	Control (n = 120)
IgG negative (0–11 IU/mL)	24 (48)	50 (37)	80 (66.7)
Low IgG concentration (12–50 IU/mL)	13 (26)	43 (31.8)	19 (15.8)
Moderate IgG concentration (51–90 IU/mL)	11 (22)	17 (12.6)	10 (8.3)
High IgG concentration (91–300 IU/mL)	2 (4)	25 (18.5)	11 (9.2)
Total IgG positive	26 (52)	85 (63)	40 (33.3)

Notes: RTR: renal transplant recipient; HD: hemodialysis group; CG: control group. p = 0.023; p values between transplant and control group. P < 0.001; p values between hemodialysis and control group.

Figure 1. Nested-PCR products of the GRA6 gene. T. gondii positive samples give a 344-bp band. M: 100 bp DNA marker; lane 1 positive control, lane 3 negative control, lanes 2, 4–11 positive samples.

Table 2. Serological findings and clinical symptoms among PCR positive patients (hemodialysis and transplant).

		ELISA
Patients no.	PCR	IgM	IgG	IgG titer (IU/mL)	Years of renal failure
1^a	+	−	+	94	I
2^a	+	−	−	8	II
3^a	+	−	−	7	III
4^a	+	−	+	59	II
5^a	+	−	−	9	I
6^a	+	−	+	75	II
7^b	+	−	+	100	I
8^b	+	+	−	8	II
9^b	+	−	+	98	II

Notes: Years of renal failure: I= 1–5 years, II =6–10 years, III >10 years.

a From the renal transplant recipient.

b From the hemodialysis patients.